Monte Rosa Therapeutics (GLUE) Current Deferred Revenue (2023 - 2026)

Monte Rosa Therapeutics' Current Deferred Revenue history runs 4 years deep, the most recent figure standing at $33.1 million for Q1 2026.

• On a quarterly basis, Current Deferred Revenue rose 1.49% year-over-year to $33.1 million in Q1 2026; TTM through Mar 2026 was $33.1 million, a 1.49% increase from a year earlier, with the FY2025 full-year figure at $111.3 million, up 589.49% from the prior year.
• Current Deferred Revenue eased to $33.1 million in Q1 2026 per GLUE's latest filing, from $111.3 million in the prior quarter.
• Across five years, Current Deferred Revenue topped out at $111.9 million in Q3 2025 and bottomed at $16.1 million in Q4 2024.
• The 4-year median for Current Deferred Revenue is $26.5 million (2024), against an average of $41.4 million.
• Biggest YoY gain for Current Deferred Revenue was 589.49% in 2025; the steepest drop was 45.2% in 2025.
• Year by year, Current Deferred Revenue stood at $17.7 million in 2023, then retreated by 8.66% to $16.1 million in 2024, then surged by 589.49% to $111.3 million in 2025, then plunged by 70.31% to $33.1 million in 2026.
• Per Business Quant, the three latest GLUE Current Deferred Revenue figures stand at $33.1 million (Q1 2026), $111.3 million (Q4 2025), and $111.9 million (Q3 2025).